Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

First Divergent Total Synthesis of (±)-Nobilin D and Structurally Related Bibenzyl Natural Products.

ACS omega·2026
Same author

A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer.

Cell chemical biology·2024
Same author

Intramolecular CH-Hydrogen Bonding During the Dissociation of the Oxaphosphetane Intermediate Facilitates Z/E-Selectivity in Wittig Olefination.

ChemistryOpen·2023
Same author

Cis- and trans-resveratrol have opposite effects on histone serine-ADP-ribosylation and tyrosine induced neurodegeneration.

Nature communications·2022
Same author

Towards resolving the enigma of the dichotomy of resveratrol: cis- and trans-resveratrol have opposite effects on TyrRS-regulated PARP1 activation.

GeroScience·2020
Same author

Dopamine Triggers CTCF-Dependent Morphological and Genomic Remodeling of Astrocytes.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2018
Same journal

Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia.

Journal of medicinal chemistry·2026
Same journal

Design, Synthesis, and Biological Evaluation of Novel PAK1/HDAC10 Dual Inhibitors That Activate Antitumor Immunity for Triple-Negative Breast Cancer Treatment.

Journal of medicinal chemistry·2026
Same journal

Conformationally Tuned Cyclic RGD Peptides for Integrin-Subtype-Selective PET/CT Imaging.

Journal of medicinal chemistry·2026
Same journal

RIMTAC: A Novel Degrader Design Platform by Indirect VHL-Recruitment via RIPK1.

Journal of medicinal chemistry·2026
Same journal

Structure-Activity Relationship of Cycling Molecular Assemblies for Golgi Targeting and Disruption.

Journal of medicinal chemistry·2026
Same journal

Rational Design of Diaryl Ether-Based Dual Inhibitors Targeting Successive Essential Enzymes HadAB and InhA in <i>Mycobacterium tuberculosis</i>.

Journal of medicinal chemistry·2026
查看所有相关文章

相关实验视频

Updated: Jun 2, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

临床上先进的BDK抑制剂

Kukkamudi Sreenivas1, Chintada Nageswara Rao1

  • 1Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia SC-29208, United States.

Journal of medicinal chemistry
|January 15, 2025
PubMed
概括
此摘要是机器生成的。

心脏病与分支链氨基酸 (BCAA) 不平衡有关. BDK的活性会影响BCAA的代谢. 一种潜在的BDK抑制剂,PF-07328948,正在为心血管疾病 (CVD) 的代谢问题进行临床试验.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

相关实验视频

Last Updated: Jun 2, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

科学领域:

  • 生物化学 生物化学
  • 心血管医学 心血管医学
  • 代谢障碍 代谢障碍 代谢障碍

背景情况:

  • 心脏和相关疾病的生理病理与分支链氨基酸 (BCAA) 代谢失衡有关.
  • BCKD激酶 (BDK) 作为BCAA催化BCKDH复合物的负调节剂.
  • 不调节BCAA代谢与心血管疾病 (CVD) 病原发生有关.

研究的目的:

  • 调查BDK在BCAA代谢功能障碍中的作用,与心脏疾病相关.
  • 评估PF-07328948,一种潜在的BDK抑制剂,其在代谢性心血管疾病中的治疗潜力.

主要方法:

  • 该研究的重点是BDK在BCAA代谢中的调节作用.
  • 临床前评估PF-07328948的类似药物的特性.
  • 目前正在进行1期临床试验,以评估PF-07328948在代谢性心血管疾病中的作用.

主要成果:

  • BCAA代谢失衡是心脏疾病病理生理学的关键因素.
  • BDK被确定为BCAA代谢功能障碍中的重要调节者.
  • PF-07328948显示出有希望的类似药物的特性,可用于潜在的治疗用途.

结论:

  • 针对BDK可能为代谢性心血管疾病提供一种新的治疗策略.
  • PF-07328948代表了临床相关的BDK抑制剂用于心血管疾病治疗.
  • 对于PF-07328948在治疗代谢性心血管疾病方面进行进一步的临床研究是有必要的.